PLEKHA7

Across TCGA pan-cancer cohorts, PLEKHA7 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLEKHA7 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PLEKHA7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLEKHA7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LIHC, UCEC, and BLCA are the cancer types where PLEKHA7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.094	0.547	<.001	21	view →
UCEC	DFS	Median	All	0.980	0.824	.003	18	view →
BLCA	OS	Median	IV	0.051	0.600	<.001	12	view →
STAD	DFS	Median	III,IV	1.000	0.328	.034	7	view →
HNSC	OS	Median	II,III,IV	0.195	0.601	.030	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLEKHA7–LIHC (DFS)

Open the LIHC breakdown →